Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

.5 million as compared to $7.4 million in the same period in 2008.

Amicus recorded revenue during the second quarter of 2009 representing two different revenue streams from the Shire agreement. Upon signing the agreement, Amicus received an upfront payment of $50 million that will be recognized as revenue on a straight-line basis over 18 years from the date of the agreement. In the second quarter of 2009, Amicus recognized $0.7 million of the Shire upfront payment and $4.7 million of research revenue on reimbursed research and development costs.

The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in Tables 2 and 3 and are primarily due to pre-tax stock compensation expense.

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP, net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

(1) Stock option expense -- Non-GAAP net loss and diluted net loss per common share exclude the impact of the stock option expense recorded in accordance with SFAS No. 123R. Amicus believes that excluding the impact of expensing stock options better reflects the recurring economic characteristics of its business.

Conference Call and Webcast'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Follow us on LinkedIn ... of cholesterol carrier or lipoprotein in the blood. Such ... levels in the body, especially along the walls of ... and other cardiovascular disorders. Cardiovascular Diseases (CVD) is the ... levels on a regular basis, to assess an individual’s ...
(Date:9/30/2014)... ORLANDO, Fla. , Sept. 30, 2014 ... is pleased to announce that it has entered into ... Biotechnologies, Inc. (Tianhe) which has licensed a series of patented ... stem cells for possible clinical applications.  Tianhe is performing ... and Spain using Tianhe,s ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... solutions for drug discovery and related life ... consortium has chosen Genedata Selector as its ... (NGS) data. FUNGITECT is a European consortium ... fungal diseases via individualized anti-fungal drug therapies. ...
(Date:9/30/2014)... CORALVILLE, Iowa , Sept. 30, 2014 /PRNewswire/ ... in the discovery and development of proprietary new ... United States Patent and Trademark Office (USPTO) issued ... patent application entitled, "Benzoic Acid, Benzoic Acid Derivatives ... Methods of Making and Use Thereof." ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... President of the Drug Information Association (DIA)-- , ... a privately held biopharmaceutical company, today announced the appointment ... vice president and chief medical officer. , , ... experience to Horizon and will lead the regulatory and ...
... REYKJAVIK, Iceland, June 29 ... ) and academic colleagues from,Iceland, the Netherlands and Denmark ... kidney stones and decreased bone mineral,density (BMD). About 60% ... in the human genome (SNP) on chromosome 21, putting,them ...
... ON, June 29 /PRNewswire-FirstCall/ - YM BioSciences Inc. ... life sciences product development company that identifies and ... at various stages of development, today reported that ... have resolved the issues between the companies in ...
Cached Biology Technology:Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer 2deCODE Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis 2deCODE Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis 3deCODE Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis 4YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 2YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 3YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG 4
(Date:10/1/2014)... 2014 Novel detection technology ... field  The life science field has ... the years. Some are shooting stars and others ... novel detection technology that has raised much enthusiasm ... technology is becoming commercially available. With their unique ...
(Date:9/30/2014)... we think of nature as something that we enjoy when ... "preserve?" Or do we think of ourselves as a part ... but what about a house? , The answers to ... in our actions, our speech and in cultural artifacts. , ... of Washington, the American Indian Center of Chicago and the ...
(Date:9/30/2014)... and Howard Hughes Medical Institute investigator, and Margarita ... in the 2014 round of grants from the ... (Brain Research through Advancing Innovative Neurotechnologies) Initiative for ... 30, provides more than $3 million in funding ... The BRAIN Initiative, launched last year, is a ...
Breaking Biology News(10 mins):First-of-a-kind Solution for Utilizing Photon Upconversion 2The cultural side of science communication 2Salk scientists receive $3 million for BRAIN Initiative grant 2
... quest for healthier, younger looking skin, scientists from ... have made an important discovery toward manipulating skin ... range from helping doctors develop more natural looking ... new products for achieving the perfect sunless tan. ...
... mediated phosphorylation is generally recognised as the major ... cells including proliferation, gene expression, motility, vesicular transport ... plays a major role in many diseases such ... elucidation of many kinase cascades has proved pivotal ...
... have struggled to chase down speeding vehicles as the movie ... fearsome carnivore was certainly no slouch, research out today suggests. ... to calculate the running speeds of five meat-eating dinosaurs that ... Tyrannosaurus. The study believed to be the most ...
Cached Biology News:Scientists discover important beauty secret for balanced skin color and tone 2All eukaryotic kinases share 1 common set of substrates 2T. rex quicker than Becks, say scientists 2
... temperature control for microbiology and cell culture. ... is suitable for DASGIP bioreactors from 150 ... temperature ranges from approximately 10 °C to ... with an individual electrical heating element with ...
... gel stain is a sensitive nucleic acid ... to RNA and low background in gels, making ... polyacrylamide gels using laser scanners or standard UV ... mL unit size (S-7568) and a special packaging ...
... reports the data from any one of IITC ... recorder. The final data is sent from the ... is automatic for Systolic, Mean, Heart Rate while ... is always in the position to override the ...
Sirtuin 7 (SIRT7) Rabbit anti-Human Polyclonal Antibody Immunogen: Synthetic peptide - KLH conjugated Family: Other Recommended Storage: Long term: -20C; Short term: +4C...
Biology Products: